↓ Skip to main content

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis

Overview of attention for article published in Arthritis Research & Therapy, June 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news
1 news outlet
twitter
1 tweeter

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
105 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Published in
Arthritis Research & Therapy, June 2016
DOI 10.1186/s13075-016-1049-3
Pubmed ID
Authors

Mark C. Genovese, Ronald F. van Vollenhoven, Bethanie Wilkinson, Lisy Wang, Samuel H. Zwillich, David Gruben, Pinaki Biswas, Richard Riese, Liza Takiya, Thomas V. Jones

Abstract

Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The aim of this study was to explore the safety and efficacy of open-label tofacitinib following blinded treatment with adalimumab or tofacitinib for moderate to severe RA. Analyses included patients treated with adalimumab 40 mg once every 2 weeks or tofacitinib 10 mg twice daily (BID) with background methotrexate (MTX) in a 12-month randomized study (NCT00853385), who subsequently received tofacitinib 10 mg BID (with/without background MTX) in an open-label extension (NCT00413699). Patients with treatment-related serious adverse events (AEs) and serious or recurrent infections in the index study were excluded from the extension study. Exposure-adjusted incidence rates of safety-related events were assessed in 3-month and 12-month periods in the year before and in the year after switching. Efficacy was assessed 3 months before, at the time of, and 3 months after switching. There were 233 (107 adalimumab to tofacitinib 10 mg BID, 126 blinded to open-label tofacitinib 10 mg BID) patients included in these analyses. Patients in both treatment sequences had similar incidence rates (per 100 patient-years) of discontinuation due to AEs, serious AEs, and serious infections in the year before and in the year after switching. Incidence rates of AEs were increased in the first 3 months after switching compared with the last 3 months before switching in both treatment groups. Switching from either blinded adalimumab or tofacitinib to open-label tofacitinib resulted in numerically higher incidence of responders for signs and symptoms of disease and improved physical function. Treatment can be directly switched from adalimumab to tofacitinib. A similar safety and efficacy profile was seen when patients received open-label tofacitinib after receiving either blinded adalimumab or tofacitinib. ClinicalTrials.gov Identifiers: NCT00853385 , registered 27 February 2009; NCT00413699 , registered 18 December 2006.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 <1%
Unknown 104 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 15 14%
Student > Master 11 10%
Student > Ph. D. Student 10 10%
Other 9 9%
Student > Bachelor 8 8%
Other 19 18%
Unknown 33 31%
Readers by discipline Count As %
Medicine and Dentistry 34 32%
Pharmacology, Toxicology and Pharmaceutical Science 12 11%
Nursing and Health Professions 4 4%
Unspecified 3 3%
Biochemistry, Genetics and Molecular Biology 3 3%
Other 9 9%
Unknown 40 38%

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 July 2016.
All research outputs
#3,132,192
of 22,879,161 outputs
Outputs from Arthritis Research & Therapy
#710
of 2,982 outputs
Outputs of similar age
#58,406
of 352,801 outputs
Outputs of similar age from Arthritis Research & Therapy
#11
of 62 outputs
Altmetric has tracked 22,879,161 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,982 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 352,801 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 62 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.